International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy

Cardoso, F., Bedard, P. L., Winer, E. P., Pagani, O., Senkus-Konefka, E., Fallowfield, L.J, Kyriakides, S., Costa, A., Cufer, T. and Albain, K. S. (2009) International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. Journal of the National Cancer Institute, 101 (17). pp. 1174-81. ISSN 0027-8874

Full text not available from this repository.

Abstract

Compared with treatment options for early-stage breast cancer, few data exist regarding the optimal use of chemotherapy for metastatic breast cancer (MBC). The choice of using a combination of cytotoxic chemotherapies vs sequential single agents is controversial. At the 6th European Breast Cancer Conference, the European School of Oncology Metastatic Breast Cancer Task Force convened an open debate on the relative benefits of combination vs sequential therapy. Based on the available data, the Task Force recommends sequential monotherapy as the preferred choice in advanced disease, in the absence of rapid clinical progression, life-threatening visceral metastases, or the need for rapid symptom and/or disease control. Patient- and disease-related factors should be used to choose between combination and sequential single-agent chemotherapy for MBC. Additional research is needed to determine the impact of therapy on patient-rated quality of life and to identify predictive factors that can be used to guide therapy.

Item Type: Article
Keywords: Age Factors Anthracyclines/administration & dosage Antineoplastic Agents/*administration & dosage Antineoplastic Combined Chemotherapy Protocols/administration & dosage Breast Neoplasms/chemistry/*drug therapy/*pathology Comorbidity Congresses as Topic Cross-Over Studies Deoxycytidine/administration & dosage/analogs & derivatives Drug Administration Schedule Europe Evidence-Based Medicine Female Fluorouracil/administration & dosage/analogs & derivatives Humans International Cooperation Karnofsky Performance Status Menopause *Patient Selection *Practice Guidelines as Topic/standards Quality of Life Randomized Controlled Trials as Topic Severity of Illness Index Socioeconomic Factors Taxoids/administration & dosage Tumor Markers, Biological/analysis Vinblastine/administration & dosage/analogs & derivatives
Schools and Departments: Brighton and Sussex Medical School > Sussex Health Outcomes Research & Education in Cancer (SHORE-C)
Subjects: R Medicine > R Medicine (General)
R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology Including cancer and carcinogens
R Medicine > RD Surgery > RD0651 Neoplasms. Tumors. Oncology
R Medicine > RG Gynecology and obstetrics > RG0491 Diseases of the breast
R Medicine > RM Therapeutics. Pharmacology > RM0260 Chemotherapy
Related URLs:
Depositing User: Tracy Woodcock
Date Deposited: 30 Apr 2012 10:43
Last Modified: 30 Nov 2012 17:12
URI: http://sro.sussex.ac.uk/id/eprint/38530
📧 Request an update